Advances of assessment with ¹⁸F-FDG PET/CT in triple-negative breast cancer during neoadjuvant chemotherapy

Triple-negative breast cancer(TNBC)is a distinctive sub-group of breast cancers that do not express estrogen receptors(ER), progesterone receptors(PR) and human epidermal growth factor receptor 2(HER2). TNBC often happens to premenopausal women, and having special features such as poor prognosis, short 5-year survival, strong tumor invasion, high incidence of local recurrence and distant metastasis. Chemotherapy and surgery are mainly available systemic treatments of TNBC, and neoadjuvant chemotherapy(NAC)has become a widely used systemic treatment. Recently, the value of ¹⁸F-FDG PET/CT in breast cancer has been extensively studied, the role of PET/CT monitoring the efficacy of NAC has been a positive result. In this paper, the research progress of assessment with ¹⁸F-FDG PET/CT in TNBC during neoadjuvant chemotherapy was reviewed.